Market Approval

 
News Articles for Market Approval top ^
2014/3/20
LYON, France, March 20, 2014 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP) , the global leader in therapeutic ultrasound, announced today that it has completed its response to questions from the FDA regarding the Company's Ablatherm-HIFU Pre-Market Approval ("PMA") application, closing this step within the U.S. Food and Drug Administration ("FDA") review process.
Sign-up for EDAP Completes FDA Q&A Session for Its Ablatherm-HIFU Pre-Market Approval Application investment picks
2014/1/17
Marketing Approval Triggers Milestone Payment to Keryx NEW YORK , Jan.
Sign-up for Keryx Biopharmaceuticals Announces Marketing Approval of Ferric Citrate in Japan investment picks
2014/2/25
BSD Medical Corporation (NASDAQ: BSDM) (Company or BSD) ( www.BSDMedical.com ), a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that BSD's exclusive Taiwan distributor, Linden Bioscience Co., Ltd., (Linden) has obtained Taiwan Food and Drug Administration (TFDA) marketing approval for the BSD-2000 Hyperthermia System (BSD-2000). Linden is a leading distributor of sophisticated medical devices in Taiwan.
Sign-up for BSD Medical Announces Taiwan Food and Drug Administration Marketing Approval for the BSD-2000 investment picks
2013/9/13
Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) , today announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has approved the use of Soliris® (eculizumab) for the treatment of pediatric and adult patients with atypical hemolytic uremic syndrome (aHUS), a life-threatening ultra-rare disorder.
Sign-up for Alexion's Soliris® (eculizumab) Receives Marketing Approval in Japan for All Patients with aHUS investment picks
2014/3/24
TOKYO , March 24, 2014 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) today announced that Astellas has obtained marketing approval of their oral androgen receptor signaling inhibitor, XTANDI ® capsules 40mg (development code: MDV3100; generic name: enzalutamide) for the treatment of patients with castration-resistant prostate cancer in Japan .
Sign-up for Astellas Announces Marketing Approval in Japan for XTANDI® (enzalutamide) Capsules, an Advanced Prostate Cancer Treatment investment picks
2013/9/30
LONDON--Drug group AstraZeneca PLC (AZN.LN) said Monday that the European Medicines Agency has accepted its marketing authorization application for Olabarib, a treatment for ovarian cancer.
Sign-up for AstraZeneca Gets European Marketing Approval for Ovarian Cancer Drug investment picks
2013/12/20
LONDON--GlaxoSmithKline PLC (GSK.LN) Friday said the European Commission has granted marketing authorization for its cervical cancer vaccine Cervarix to be administered in two doses instead of three in girls aged nine to 14.
Sign-up for Glaxo Gets Marketing Approval For Cervical Cancer Dose Reduction investment picks
2014/3/26
By Rory Gallivan LONDON--Drug group GlaxoSmithKline PLC (GSK.LN) Wednesday said the European Commission has granted marketing authorization for its once-weekly diabetes treatment Eperzan.
Sign-up for GlaxoSmithKline: EU Grants Marketing Approval for Diabetes Drug Eperzan investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Market Approval
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Market Applicability  |  Next: Market Association